CONCORD Intrinsic Valuation and Fundamental Analysis - Concord Drugs Ltd

Watchlist Manager

Watchlist

Price: 68 INR 1.63%

Market Cap: ₹896.2m

C	Concord Drugs Ltd BSE:538965	IN
	Lifecore Biomedical Inc F:LDE	US
S	Sumitomo Mitsui Financial Group, Inc LSE:0LAF	JP
E	Evoke PLC OTC:EIHDF	GI
R	Retailors Ltd TASE:RTLS	IL
E	Equifax Inc F:EFX	US
	Rain Industries Ltd NSE:RAIN	IN
A	Assystem SA F:BZ1	FR

Intrinsic Value

538965 price has not been updated for more than 3 years. This may indicate that the stock has been delisted.

538965 doesn't have a meaningful market cap.

Is CONCORD undervalued or overvalued?

See the intrinsic value estimate for Concord Drugs Ltd and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

CONCORD Intrinsic Value

Unlock

Today vs. history

See how today’s valuation compares with CONCORD’s past valuations and how the stock performed after similar periods.

See what happened next Free account required

Track Buy Zone

20% below Intrinsic Value

Get notified when the price drops into your buy zone

Intrinsic Value Locked

Margin of Safety 20% Locked

Current Price ₹68

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Fundamental Analysis

What Concord Drugs Does

Pharmaceuticals Health Care

Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-02-23. The firm is engaged in manufacturing of licensed drugs based on the formulations approved. The firm offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup & suspension) and dry syrups (powder).

Headquarters: India IN
IPO date: Feb 23, 2015